BIVI Quote, Financials, Valuation and Earnings

iBio has a net margin of -- compared to BioVie's net margin of -4444.57%. BioVie's return on equity of -- beat iBio's return on equity of -148.3%.

BioVie has a consensus price target of --, signalling upside risk potential of 163.16%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 45.16%. Given that BioVie has higher upside potential than iBio, analysts believe BioVie is more attractive than iBio.

BioVie has a beta of 0.933, which suggesting that the stock is 6.69% less volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

BioVie quarterly revenues are --, which are smaller than iBio quarterly revenues of $175K. BioVie's net income of -$4.2M is lower than iBio's net income of -$4M. Notably, BioVie's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

MediciNova has a net margin of -- compared to BioVie's net margin of --. BioVie's return on equity of -- beat MediciNova's return on equity of --.

BioVie has a consensus price target of --, signalling upside risk potential of 163.16%. On the other hand MediciNova has an analysts' consensus of -- which suggests that it could grow by 287.6%. Given that MediciNova has higher upside potential than BioVie, analysts believe MediciNova is more attractive than BioVie.

BioVie has a beta of 0.933, which suggesting that the stock is 6.69% less volatile than S&P 500. In comparison MediciNova has a beta of 0.844, suggesting its less volatile than the S&P 500 by 15.569%.

BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MediciNova offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. MediciNova pays out -- of its earnings as a dividend.

BioVie quarterly revenues are --, which are smaller than MediciNova quarterly revenues of --. BioVie's net income of -$4.2M is lower than MediciNova's net income of -$2.9M. Notably, BioVie's price-to-earnings ratio is -- while MediciNova's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus -- for MediciNova. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to BioVie's net margin of -49.65%. BioVie's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

BioVie has a consensus price target of --, signalling upside risk potential of 163.16%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than BioVie, analysts believe NovaBay Pharmaceuticals is more attractive than BioVie.

BioVie has a beta of 0.933, which suggesting that the stock is 6.69% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

BioVie quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. BioVie's net income of -$4.2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, BioVie's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to BioVie's net margin of -2357.27%. BioVie's return on equity of -- beat Palatin Technologies's return on equity of --.

BioVie has a consensus price target of --, signalling upside risk potential of 163.16%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than BioVie, analysts believe Palatin Technologies is more attractive than BioVie.

BioVie has a beta of 0.933, which suggesting that the stock is 6.69% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

BioVie quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. BioVie's net income of -$4.2M is higher than Palatin Technologies's net income of -$7.8M. Notably, BioVie's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.